Advancing Psilocybin Drug Development
Psilocin Pharma Corp.
About
Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body’s own natural pathways of absorption while offering a contemporary approach to consumption.
Revive Therapeutics has partnered with leading institutions for development of Psilocin’s Pharma platform.
News
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application
TORONTO, March 19, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce positive...
Revive Therapeutics Acquires Unique Psilocybin Assets
TORONTO, Feb. 17, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that, further...
Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin
TORONTO, Jan. 14, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered...